<DOC>
	<DOCNO>NCT01037543</DOCNO>
	<brief_summary>Study Design - Randomized , double-blind , placebo-controlled , escalate single-dose design . - Six ascend dose cohort - In cohort , subject randomize receive single dose HM10460A , placebo ( negative control ) , NeulastaÂ® ( positive control ) . - Primary Objective - ass safety tolerability single escalate subcutaneous dos HM10460A healthy adult Japanese Caucasian subject .</brief_summary>
	<brief_title>Safety PK HM10460A ( HNK460 ) Healthy Adult Japanese Caucasian Subjects</brief_title>
	<detailed_description>Secondary objective : - ass pharmacokinetics ( PK ) single subcutaneous dose HM10460A . - compare PK HM10460A Japanese Caucasian subject . - ass relationship serum concentration HM10460A absolute neutrophil count ( ANC ) . - ass relationship serum concentration HM10460A CD34+ cell count blood . - To assess immunogenicity potential HM10460A measure bind antibody ( bAb ) neutralize antibody ( nAb ) HM10460A native G-CSF follow single subcutaneous dose HM10460A .</detailed_description>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>BMI 18 29.9 kg/m2 use tobacco nicotine contain product least 3 month prior dose able remain abstinent throughout study . History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease . positive urine drug/alcohol test Positive HIV , HBsAg , HCV ab History anaphylactic reaction medicine environmental exposure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>